Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer is a phase 2/3, randomised interventional study registered as NCT03637816 by M.D. Anderson Cancer Center, with a registry enrolment figure of 25 participants, started 2018-11-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: Anamorelin Hydrochloride; Placebo; Questionnaire Administration. Conditions listed: Anorexia; Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer. Primary outcome: To reach thematic saturation by qualitatively examining experiences related to anorexia at the baseline in advanced lung cancer patients with anorexia/cachexia receiving either oral Anamorelin 100 mg or placebo.. Lung eligibility wording from the registry: "* Patients with a diagnosis of advanced non-small cell lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.